

Jason M Pogue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9470017/publications.pdf>

Version: 2024-02-01

96
papers

3,756
citations

218662

26
h-index

138468

58
g-index

100
all docs

100
docs citations

100
times ranked

5403
citing authors

#	ARTICLE	IF	CITATIONS
1	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39.	2.6	545
2	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2021, 73, e445-e454.	5.8	350
3	Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System. <i>Clinical Infectious Diseases</i> , 2011, 53, 879-884.	5.8	277
4	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa105.	0.9	255
5	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 213-225.	9.1	255
6	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	178
7	Agents of Last Resort. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 391-414.	5.1	135
8	Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020, 71, 304-310.	5.8	126
9	Carbapenem-resistant <i>Acinetobacter baumannii</i> : epidemiology, surveillance and management. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 383-393.	4.4	118
10	Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. <i>Clinical Infectious Diseases</i> , 2019, 68, 519-524.	5.8	118
11	Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms. <i>Infectious Diseases and Therapy</i> , 2020, 9, 17-40.	4.0	114
12	Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. <i>Virulence</i> , 2017, 8, 403-416.	4.4	93
13	Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant <i>A. baumannii</i> : A Review. <i>Infectious Diseases and Therapy</i> , 2017, 6, 199-211.	4.0	70
14	Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. <i>Drugs</i> , 2019, 79, 243-269.	10.9	69
15	Making the change to area under the curveâ€‘based vancomycin dosing. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1986-1995.	1.0	68
16	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. <i>Clinical Microbiology and Infection</i> , 2021, 27, 671-686.	6.0	54
17	Automated Alerts Coupled with Antimicrobial Stewardship Intervention Lead to Decreases in Length of Stay in Patients with Gram-Negative Bacteremia. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 132-138.	1.8	50
18	Polymyxin B in combination with meropenem against carbapenemase-producing <i>Klebsiella pneumoniae</i> : pharmacodynamics and morphological changes. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 224-232.	2.5	46

#	ARTICLE	IF	CITATIONS
19	Outcomes of carbapenem-resistant Enterobacteriaceae isolation: Matched analysis. American Journal of Infection Control, 2014, 42, 612-620.	2.3	43
20	Revisiting “Older” Antimicrobials in the Era of Multidrug Resistance. Pharmacotherapy, 2011, 31, 912-921.	2.6	42
21	Antibiotic Overuse After Hospital Discharge: A Multi-hospital Cohort Study. Clinical Infectious Diseases, 2021, 73, e4499-e4506.	5.8	40
22	Polymyxin-Resistant Acinetobacter baumannii: Urgent Action Needed. Clinical Infectious Diseases, 2015, 60, 1304-7.	5.8	38
23	An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	34
24	Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	32
25	Risk factors for bloodstream infection caused by extended-spectrum β -lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime. American Journal of Infection Control, 2015, 43, 719-723.	2.3	31
26	Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. Open Forum Infectious Diseases, 2021, 8, ofab434.	0.9	31
27	Impact of Different Antimicrobial Therapies on Clinical and Fiscal Outcomes of Patients with Bacteremia Due to Vancomycin-Resistant Enterococci. Antimicrobial Agents and Chemotherapy, 2014, 58, 3968-3975.	3.2	27
28	The Verigene dilemma: gram-negative polymicrobial bloodstream infections and clinical decision making. Diagnostic Microbiology and Infectious Disease, 2018, 91, 144-146.	1.8	26
29	Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. Journal of Antibiotics, 2013, 66, 625-627.	2.0	25
30	Intravenous fosfomycin for the treatment of hospitalized patients with serious infections. Expert Review of Anti-Infective Therapy, 2017, 15, 935-945.	4.4	25
31	Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?. International Journal of Antimicrobial Agents, 2016, 48, 622-626.	2.5	24
32	Role of Unit-Specific Combination Antibigrams for Improving the Selection of Appropriate Empiric Therapy for Gram-Negative Pneumonia. Infection Control and Hospital Epidemiology, 2011, 32, 289-292.	1.8	23
33	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. Infectious Diseases and Therapy, 2020, 9, 561-572.	4.0	23
34	The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections. Open Forum Infectious Diseases, 2020, 7, ofaa161.	0.9	23
35	Agents of Last Resort. Infectious Disease Clinics of North America, 2020, 34, 723-750.	5.1	22
36	Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infectious Diseases, 2022, 22, 36.	2.9	21

#	ARTICLE	IF	CITATIONS
37	Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β -Lactamase-producing <i>Klebsiella pneumoniae</i> . <i>American Journal of Infection Control</i> , 2011, 39, 390-395.	2.3	19
38	Nephrotoxicity Comparison of Two Commercially Available Generic Vancomycin Products. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5470-5474.	3.2	16
39	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. <i>Infectious Diseases and Therapy</i> , 2020, 9, 525-536.	4.0	16
40	Critical Need for Clarity in Polymyxin B Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	15
41	Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Infectious Diseases</i> , 2019, 68, S223-S232.	5.8	15
42	Toxicity in Patients. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 289-304.	1.6	13
43	Assessment of Testing and Treatment of Asymptomatic Bacteriuria Initiated in the Emergency Department. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa537.	0.9	13
44	<i>In Vitro</i> Assessment of Combined Polymyxin B and Minocycline Therapy against <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
45	Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2405-2410.	3.0	12
46	Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. <i>Clinical Infectious Diseases</i> , 2020, 71, 3033-3041.	5.8	10
47	Is there really no benefit to combination therapy with colistin?. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 881-884.	4.4	9
48	The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals. <i>Hospital Pharmacy</i> , 2015, 50, 180-184.	1.0	8
49	Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa278.	0.9	8
50	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa084.	0.9	8
51	Antimicrobial Stewardship for the Infection Control Practitioner. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 771-784.	5.1	7
52	Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant <i>Serratia marcescens</i> and <i>Enterobacter aerogenes</i> bacteraemia in a haemodialysis patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3529-3531.	3.0	7
53	Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , 2019, 8, 199-208.	4.0	7
54	Asymptomatic bacterisputia: Rethinking diagnostic stewardship in pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 737-739.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Temporal Trends in Antimicrobial Prescribing During Hospitalization for Potential Infection and Sepsis. <i>JAMA Internal Medicine</i> , 2019, 179, 10, 1100-1107.	5.1	6
56	Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. <i>Journal of Infection and Public Health</i> , 2014, 7, 50-53.	4.1	5
57	Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?. <i>Clinical Infectious Diseases</i> , 2016, 63, 1613-1614.	5.8	4
58	1562. Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity. <i>Open Forum Infectious Diseases</i> , 2019, 6, S570-S570.	0.9	4
59	Carbapenem-Susceptible <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> Isolates Carrying a Truncated KPC Carbapenemase: a Challenge for Rapid Molecular Diagnostics. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	4
60	Antimicrobial Stewardship and the Infection Control Practitioner. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 771-787.	5.1	4
61	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20525.	3.7	4
62	Extended-spectrum β -lactamase-producing <i>Escherichia coli</i> isolation among older adults: Epidemiology and outcomes. <i>American Journal of Infection Control</i> , 2014, 42, 565-568.	2.3	3
63	Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2053-2057.	1.8	3
64	Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia Coli</i> Infections in Metro Detroit: Early Dominance of the ST-131 Clone. <i>Infectious Diseases and Therapy</i> , 2020, 9, 683-690.	4.0	3
65	The Clinical Impact of a Negative Molecular β -Lactamase Gene Test for <i>Enterobacteriaceae</i> : Let's Not Let Perfect Be the Enemy of Really Good. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	3
66	Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab268.	0.9	3
67	521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2019, 6, S251-S251.	0.9	2
68	Reply to Vena et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 1801-1802.	5.8	2
69	2406. Real-world Treatment of Multidrug-Resistant (MDR) or Extensively Drug-Resistant (XDR) <i>P. aeruginosa</i> Infections With Ceftolozane/Tazobactam (C/T) vs. a Polymyxin or Aminoglycoside (Poly/AG)-based Regimen: A Multicenter Comparative Effectiveness Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S719-S719.	0.9	1
70	2890. Antibiotic Overuse at Discharge in Hospitalized Patients with Bacteriuria or Treated for Pneumonia: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S78-S79.	0.9	1
71	Recommended Revisions to the National Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. <i>Pharmacotherapy</i> , 2020, 40, 368-371.	2.6	1
72	The role of tazobactam-based combinations for the management of infections due to extended-spectrum β -lactamase-producing <i>Enterobacterales</i> : Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2021, 41, 864-880.	2.6	1

#	ARTICLE	IF	CITATIONS
73	842. Impact of Active Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections in US Hospitals Between 2014 and 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, S462-S462.	0.9	1
74	630. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. <i>Open Forum Infectious Diseases</i> , 2021, 8, S418-S419.	0.9	1
75	638. The Impact of <i>in vitro</i> Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-resistant Gram-negative Infections: A Report from the OVERCOME Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S421-S422.	0.9	1
76	Polymyxins in 2015: It's Like Dã©jã Vu All Over Again. <i>Pharmacotherapy</i> , 2015, 35, 9-10.	2.6	0
77	Reply to Manian. <i>Clinical Infectious Diseases</i> , 2017, 65, 178-179.	5.8	0
78	2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program and Rapid Genotypic Organism/Resistance Marker Identification. <i>Open Forum Infectious Diseases</i> , 2018, 5, S606-S606.	0.9	0
79	1811. Minimizing Time to Optimal Therapy for Enterobacteriaceae Bloodstream Infections: Is Organism Identification Enough?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S514-S514.	0.9	0
80	1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against <i>Pseudomonas aeruginosa</i> (PA) as a Case Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S437-S437.	0.9	0
81	1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S453-S454.	0.9	0
82	2366. Treatment Characteristics and Predictors of Mortality in Patients With Infected Chronic Pressure Ulcers in Detroit. <i>Open Forum Infectious Diseases</i> , 2018, 5, S704-S704.	0.9	0
83	2415. Comparison of Minocycline MICs Obtained by Etest to Those Obtained by Broth Microdilution in a Bank of Isolates of <i>Acinetobacter baumannii</i> Collected in Southeastern Michigan. <i>Open Forum Infectious Diseases</i> , 2018, 5, S722-S722.	0.9	0
84	1600. Susceptibility of β -Lactam-Resistant <i>Pseudomonas aeruginosa</i> to Other β -Lactams: Is There Truly a Lack of Cross-Resistance?. <i>Open Forum Infectious Diseases</i> , 2019, 6, S583-S584.	0.9	0
85	2193. Factors Impacting the Duration of Antimicrobial Therapy for Community-Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S746-S747.	0.9	0
86	522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of <i>Pseudomonas aeruginosa</i> at a Large Academic Tertiary Care Hospital. <i>Open Forum Infectious Diseases</i> , 2019, 6, S251-S252.	0.9	0
87	1106. Assessment of Fluoroquinolone Appropriateness for Hospitalized Patients with Asymptomatic Bacteriuria and Cystitis: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S393-S394.	0.9	0
88	1083. Risk Factors Associated with Treatment of Asymptomatic Bacteriuria in the Emergency Department: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S384-S385.	0.9	0
89	1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Bloodstream Infections (BSI). <i>Open Forum Infectious Diseases</i> , 2019, 6, S582-S582.	0.9	0
90	551. Burden of Illness in Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections in US Hospitals (2014 to 2018). <i>Open Forum Infectious Diseases</i> , 2019, 6, S262-S262.	0.9	0

#	ARTICLE	IF	CITATIONS
91	1185. Impact of Utilizing Drug Resistance in Pneumonia (DRIP) Score on Management of Pneumonia. Open Forum Infectious Diseases, 2019, 6, S425-S425.	0.9	0
92	1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for <i>P. aeruginosa</i> , <i>A. baumannii</i> , and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Open Forum Infectious Diseases, 2019, 6, S559-S559.	0.9	0
93	848. Trends of Carbapenem Resistance in Enterobacterales in the US Between 2015 and 2019. Open Forum Infectious Diseases, 2020, 7, S464-S464.	0.9	0
94	642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation. Open Forum Infectious Diseases, 2021, 8, S423-S423.	0.9	0
95	1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients. Open Forum Infectious Diseases, 2021, 8, S651-S651.	0.9	0
96	786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) <i>Pseudomonas aeruginosa</i> (PSA) From 2016-2019: A Multicenter Evaluation. Open Forum Infectious Diseases, 2021, 8, S490-S490.	0.9	0